ZyVersa Therapeutics to Present Kidney Disease Drug VAR 200 at JPM Healthcare Conference 2025
核心洞察
ZyVersa Therapeutics' CEO, Stephen C. Glover, will attend the JPM Healthcare Conference in January 2025 to discuss the company's pipeline.
VAR 200, a Cholesterol Efflux (搜索) Mediator, is set to begin Phase 2a clinical trials for diabetic kidney disease (搜索) in Q1 2025.
IC 100, an Inflammasome ASC (搜索) Inhibitor, is being developed for obesity (搜索) with metabolic complications, including cardiovascular disease (搜索).
ZyVersa Therapeutics Inc. (Nasdaq: ZVSA) will present its investigational drug, VAR 200, for kidney diseases at JPM's 43rd Annual Healthcare Conference in San Francisco from January 13-16, 2025. CEO Stephen C. Glover will be available for one-on-one meetings to discuss the company's technology and pipeline assets.
ZyVersa is developing VAR 200, a Cholesterol Efflux (搜索) Mediator, for diabetic kidney disease (搜索), with Phase 2a clinical trials expected to begin in Q1 2025. The company is also advancing IC 100, an Inflammasome ASC (搜索) Inhibitor, targeting obesity (搜索) with metabolic complications such as cardiovascular disease (搜索).
VAR 200: Addressing Diabetic Kidney Disease
VAR 200 is designed to mediate the removal of renal lipids and cholesterol that contribute to kidney damage and disease. Diabetic kidney disease (搜索) (DKD) is a leading cause of chronic kidney disease (搜索) and end-stage renal disease worldwide. Current treatments often fail to halt the progression of DKD, highlighting the need for new therapeutic options.
IC 100: Targeting Inflammatory Pathways in Obesity
IC 100, a monoclonal antibody, is designed to attenuate the initiation and perpetuation of disease-causing inflammation. Its lead indication is obesity (搜索) with metabolic complications, including cardiovascular disease (搜索). Obesity is a significant global health concern, often associated with chronic inflammation and increased risk of metabolic and cardiovascular disorders.
ZyVersa's Pipeline and Strategy
ZyVersa is a clinical-stage specialty biopharmaceutical company focused on developing first-in-class drugs for inflammatory and renal diseases. The company's pipeline is built around two proprietary technologies: Inflammasome ASC (搜索) Inhibition and Cholesterol Efflux (搜索) Mediation. According to ZyVersa, the total accessible market for these therapeutic areas is over $100 billion.
Stephen Glover stated, "We look forward to meeting with industry strategics and investors during JPM 2025 to discuss the value building opportunities expected with our highly differentiated Inflammasome ASC (搜索) Inhibitor IC 100 and Cholesterol Efflux (搜索) Mediator™ VAR 200."